Brendan J Connell MD

Oncology•Boston, MA

Genitourinary Oncology

Physician

Join to View Full Profile

41 Mall RoadLahey Hospital and Medical CenterBoston, MA 01805
Phone+1 781-744-8400
Fax+1 781-744-5245

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Lahey ClinicChief Residency, Internal Medicine, 2014 - 2015
Lahey ClinicResidency, Internal Medicine, 2011 - 2014
Royal College of Surgeons IrelandClass of 2011
Harvard UniversityBA, 2005

Certifications & Licensure

FL State Medical License 2024 - Present
MA State Medical License 2013 - 2026
NH State Medical License 2024 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2018 Jan 30
ACTIVE_NOT_RECRUITING
PHASE1
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Start of enrollment: 2019 May 13
RECRUITING
PHASE2
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate Start of enrollment: 2020 Mar 31
Active, not recruiting
Phase 3
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Start of enrollment: 2021 Mar 01
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) Start of enrollment: 2021 Feb 25
ACTIVE_NOT_RECRUITING
PHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) Start of enrollment: 2021 Apr 14
ACTIVE_NOT_RECRUITING
PHASE3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial Start of enrollment: 2021 Dec 06
RECRUITING
PHASE3
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study Start of enrollment: 2022 Jun 30
RECRUITING
PHASE2
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study Start of enrollment: 2024 Feb 02
RECRUITING
PHASE2, PHASE3
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Start of enrollment: 2023 Dec 11
RECRUITING
PHASE1, PHASE2
Join now to see all

Publications & Presentations

PubMed

Testosterone therapy in patients with locoregional prostate cancer treated with prior androgen deprivation therapy and radiation: a retrospective single center review.
Mostafa Aglan, Yixin Kong, Brendan Connell
Translational Andrology and Urology. 2025-02-28
Associations of SGLT2i with Cardiorenal Outcomes Among Diabetics with Prostate Cancer on Hormone Therapy.
Efstratios Koutroumpakis, Rushin Patel, Sumanth Khadke, Aram Bedrosian, Ashish Kumar
Cardiovascular Drugs and Therapy. 2024-11-11
3 citations
Safety of sequential immune checkpoint inhibitors after prior immune therapy.
Muhammad Awidi, Brendan Connell, Delaney Johnson, Isabel Craven, Rojer Ranjit
Journal of Cancer Research and Clinical Oncology. 2023-06-01

Abstracts/Posters

Fractionated docetaxel and radium-223 (Ra223) in metastatic castration-resistant prostate cancer (CRPC): A phase I trial.
Brendan James Connell, Edmund Folefac, Clara Hwang, Christian Lawlor, Paul Mathew, GU ASCO 2021, 2/2021

Lectures

Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs).
2019 ASCO Annual Meeting - 6/1/2019

Brendan J Connell MD

Dr. Connell is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Viewing the full profile is available to verified healthcare professionals only.